Eli Lilly Expands Oncology Pipeline with $7 Billion Kelonia Acquisition

Eli Lilly announced Monday its acquisition of Kelonia Therapeutics in a deal valued at up to $7 billion, marking a strategic push into the hematology market. The transaction is expected to close in the second half of 2026. The acquisition centers on Kelonia's in vivo CAR-T technology, which allows for the reprogramming of a patient's T-cells directly within the body. This represents a significant shift from traditional ex vivo therapies, which require cells to be harvested, engineered in a laboratory, and then reintroduced to the patient—a process that is logistically intensive and typically limited to specialized academic medical centers. Under the terms of the agreement, Lilly will provide $3.25 billion in upfront cash. The remaining balance is contingent upon the achievement of specific clinical, regulatory, and commercial milestones. Jacob Van Naarden, president of Lilly oncology, described the technology as a one-time intravenously delivered therapy that requires no preconditioning. The move places Lilly in direct competition with other pharmaceutical giants in the cell therapy space. Johnson & Johnson's Carvykti, an ex vivo treatment for multiple myeloma, generated $1.89 billion in sales last year, while Gilead recently spent $7.8 billion to acquire Arcellx and its rival drug, anito-cel. By eliminating the need for complex laboratory engineering, Lilly aims to make advanced cell therapy more broadly accessible to patients and physicians, expanding its footprint in the treatment of blood cancers.